Regeneron PharmaceuticalsREGNRevenue: is the business selling more than it used to?
$14.3B+1% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $14.3B in 2025, compounding +6% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $15.5B, ahead of the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNNet income: how much of that revenue becomes profit?
$4.5B+2% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $4.5B in 2025, compounding +1% a year over three years. Trailing twelve-month profit stands at $4.3B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNHow fast is it growing, year by year?
+1.0%revenue growth, FY 2025
→Revenue grew +1% in 2025 against a five-year average of +16%. Earnings grew faster (+2%), so each new dollar of sales is arriving more profitably.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNRevenue per share: is your slice growing as fast as the company?
$132.07revenue per share, FY 2025
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Revenue per share reached $132.07 in 2025, compounding +7% a year against +6% for REGN as a whole. Buybacks added roughly 1.6 points to your per-share result. Free cash flow per share stands at $37.57.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNFree cash flow: what is left in real cash after everything?
$4.1B+11% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow was $4.1B in 2025, compounding -3% a year since 2022. The trailing twelve months stand at $3.8B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNHow much of every sales dollar ends up as free cash?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→28 cents of every sales dollar became free cash in 2025, down 8 points since 2022.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNWhat does staying competitive cost, per dollar of sales?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The biggest claim on each sales dollar is research and development, at 41% of revenue (stock compensation 7%, capital spending 6%). That share has risen since 2022, so the cost of competing is climbing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNWhen sales grow, do profits grow faster?
→Operating profit outgrew revenue in only 1 of the last 5 years. Costs are growing roughly in step with the business, so scale isn't yet paying for itself.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNMargins: of every $1 of sales, how much survives each cost layer?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Operating margin compressed 14 points to 25% since 2022. After everything, 31 cents of each sales dollar reaches net profit. REGN doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNWhat does it earn on the money it uses?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→ROE of 14% and ROCE of 10% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNWhat has the market paid for REGN over time?
20.8xP/E today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 20.8x earnings, the market is paying +13% more than REGN's own 11-year median of 18.4x. Expectations are elevated, so more has to go right to justify the price.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNWhat cash return does the business throw off per dollar of market value?
4.8%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 4.8% of annual free cash flow, right at REGN's 11-year median of 4.4%.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNCould it handle its debt if things went wrong?
→The company holds $2.5B in cash against $2.0B of debt - a net-cash balance sheet, which means a bad year is an inconvenience rather than a threat.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNIs the company's own capital growing?
→The company's own capital grew from $26.0B in 2023 to $31.7B (+22%). The business is building book value rather than consuming it.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNHow much goes back, and how much leaks out as stock comp?
→Shareholders received $3.4B in buybacks and $370M in dividends in 2025. Stock compensation issued $994M of new shares in the same year, offsetting 26% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNHow fast is your ownership being diluted - or concentrated?
→The share count shrank 5.6% in 2025, averaging 1.4% a year over three years. Buybacks are concentrating your ownership: the same business, split fewer ways.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNDoes REGN earn more on its capital than that capital costs?
→REGN earns 9.9% on the capital it employs, below the 10% most investors treat as the cost of capital. It was 18.2% in 2022, so the trend is down, though the pace has cooled.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNREGN has issued or retired shares - did shareholders end up better off?
→REGN issued +20% more shares from 2011 to 2025, but revenue per share still rose +2584%. The dilution bought more growth than it cost existing holders.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Regeneron PharmaceuticalsREGNAre the people running it buying or selling?
→Insiders sold $8M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 9 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30